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Abstract
Background: The success of targeted anti-cancer drugs are frequently hindered by the lack of knowledge of the
individual pathway of the patient and the extreme data requirements on the estimation of the personalized genetic
network of the patient’s tumor. The prediction of tumor sensitivity to targeted drugs remains a major challenge in the
design of optimal therapeutic strategies. The current sensitivity prediction approaches are primarily based on genetic
characterizations of the tumor sample. We propose a novel sensitivity prediction approach based on functional
perturbation data that incorporates the drug protein interaction information and sensitivities to a training set of drugs
with known targets.
Results: We illustrate the high prediction accuracy of our framework on synthetic data generated from the Kyoto
Encyclopedia of Genes and Genomes (KEGG) and an experimental dataset of four canine osteosarcoma tumor
cultures following application of 60 targeted small-molecule drugs. We achieve a low leave one out cross validation
error of < 10% for the canine osteosarcoma tumor cultures using a drug screen consisting of 60 targeted drugs.
Conclusions: The proposed framework provides a unique input-output based methodology to model a cancer
pathway and predict the effectiveness of targeted anti-cancer drugs. This framework can be developed as a viable
approach for personalized cancer therapy.
Background
In the last decade, a number of drugs targeting specific
biologically relevant kinases have been developed that are
becoming common in cancer research as a basis for per-
sonalized therapy. The idea of treating cancer through
inhibition of a specific tyrosine kinase was proven by the
discovery that patients with Chronic Myeloid Leukemia
can be successfully treated by inhibiting the tyrosine
kinase BCR-ABL with the kinase inhibitor ImatinibMesy-
late [1]. However, the success rate of any one specific
targeted drug for other forms of cancer, such as sarcoma,
is limited as the tumors exhibit a wide variety of signaling
pathways and are not uniformly dependent on the activity
of a specific kinase [2-6].
The numerous aberrations in molecular pathways that
can produce cancer is one cause to necessitate the use
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of drug combinations for treatment of individual can-
cers. Combination therapy design requires a framework
for inference of the individual tumor pathways, prediction
of tumor sensitivity to targeted drug(s) and algorithms for
selection of the drug combinations under different con-
straints. The current state of the art in predicting sensitiv-
ity to drugs is primarily based on assays measuring gene
expression, protein abundance and genetic mutations of
tumors; these methods often have low accuracy due to
the breadth of available expression data coupled with
the absence of information on the functional importance
of many genetic mutations. A commonly used method
for predicting the success of targeted drugs for a tumor
sample is based on the genetic aberrations in the tumor
(e.g. mutation, amplification). However, the accuracy of
prediction of drug sensitivity based on mutation knowl-
edge is limited in many forms of tumors as some of the
mutations (or low frequency polymorphisms) may not be
functionally important or tumors can develop without the
known genetic mutations. Statistical tests have been used
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in [7] to show that genetic mutations can be predictive
of the drug sensitivity in non-small cell lung cancers but
the classification rates of these predictors based on indi-
vidual mutations for the aberrant samples are still low.
For specific diseases, some mutations have been able to
predict the patients that will not respond to particular
therapies: for instance [8] reports a success rate of 87%
in predicting non-responders to anti-EGFR monoclonal
antibodies using the mutational status of KRAS, BRAF,
PIK3CA and PTEN. The prediction of tumor sensitivity to
drugs has also been approached as a classification prob-
lem using gene expression profiles. In [9], gene expression
profiles are used to predict the binarized efficacy of a drug
over a cell line with the accuracy of the designed classi-
fiers ranging from 64% to 92%. In [10], a co-expression
extrapolation (COXEN) approach is used to predict the
binarized drug sensitivity in data points outside the train-
ing set with an accuracy of around 75%. In [11], a Random
Forest based ensemble approach was used for predic-
tion of drug sensitivity and achieved an R2 value of
0.39 between the predicted IC50s and experimental IC50s.
Supervised machine learning approaches using genomic
signatures achieved a specificity and sensitivity of higher
than 70% for prediction of drug response in [12]. Tumor
sensitivity prediction has also been considered as (a) a
drug-induced topology alteration [13] using phospho-
proteomic signals and prior biological knowledge of a
generic pathway and (b) a molecular tumor profile based
prediction [7,14].
Most interestingly, in the recent cancer cell line ency-
clopedia (CCLE) study [15], the authors characterize a
large set of cell lines (> 900) with numerous associated
data measurement sets: gene and protein expression pro-
files, mutation profiles, methylation data along with the
response of around 500 of these cells lines across 24 anti-
cancer drugs. One of the goals of the study was to enable
predictive modeling of cancer drug sensitivity. For gener-
ating predictivemodels, the authors considered regression
based analysis across input features of gene and protein
expression profiles, mutation profiles and methylation
data. The performance (as measured by Pearson corre-
lation coefficient between predicted and observed sensi-
tivity values) of the predictive models using 10 fold cross
validation ranged between 0.1 to 0.8. In particular, the
correlation coefficient for prediction of sensitivity using
genomic signatures for the drug Erlotinib across > 450
cell lines was < 0.35. Erlotinib is a commonly used
tryosine kinase inhibitor selected primarily as an EGFR
inhibitor. However, studies have shown [16] that these tar-
geted drugs often have numerous side targets that can play
significant roles in the effectiveness of the inhibitor drugs.
The target inhibition profiles of drugs and sensitivity of
trainings set of drugs can provide significant information
for enhanced prediction of anti-cancer drug sensitivity as
we have recently shown [17]. By incorporating the drug-
target interaction data and sensitivities of training drugs
with genomic signatures, we were able to achieve a cor-
relation coefficient of 0.79 (more than 2 fold increase in
correlation coefficient) for prediction of Erlotinib sensi-
tivity using 10 fold cross validation. The result illustrates
the fundamental concept of the importance of drug-target
interaction and functional data under which we develop
the sensitivity prediction method presented in this paper.
By developing a framework around the functional and tar-
get information extracted from the primary tumor drug
screen performed by our collaborators, we seek to develop
a cohesive approach to sensitivity prediction and com-
bination therapy design. This necessitates the generation
of the tumor pathway structure for individual patients to
decide on the target inhibitors for therapy based on the
personalized patient pathways.
We envision that the overall schematic of the design of
personalized pathways and personalized therapy will be
similar to the workflow shown in Figure 1.
The explanations of the various steps in the design
process are as follows:
(Steps A-B) A patient is diagnosed with cancer
and a primary culture of the tumor is
established.
(Step C) Cell viability after exposure to
targeted drugs is measured through a
drug screen. Use of this functional
data rather than mutation or protein
biomarkers provides a unique
advantage.
(Step D) A target inhibition map (TIM) is
generated based on the IC50′s and the
known targets of the drugs in the
screen. TIM denotes a predictive
model that provides the sensitivity
for all possible target inhibitions.
Specifically, a TIM is composed of a
set T = {T1,T2, · · · ,Tn} consisting
of binary variables, each denoting
inhibition of a target, and a function f
relating the target inhibitions to the
steady state sensitivity yT , i.e.
yT = f (T1,T2, · · · ,Tn). The
inhibition vector (e1, e2, · · · , en)
corresponding to a drug is known as
the Drug Target Inhibition Profile
(DTIP). A detailed example of TIM is
provided in Additional file 1. The
coarse structure of the TIM can also
be represented by an abstract
pathway which will be termed TIM
Circuit. The construction of the TIM












Figure 1 Combination therapy design workflow: various steps in the design of combination targeted therapy.
Circuit is explained in the methods
section.
(Steps E1-E2) Further data is collected using siRNA
screens [18], RNA sequencing and
Protein phosphoarrays to reduce
model parameter uncertainties.
(Steps F1-F2) Based on the knowledge of the TIM
and TIM-directed protein expression
measurements, the dynamic model is
created.
(Step G) Combination therapy is designed
utilizing the personalized TIM and
the dynamic model (if estimated).
Various constraints such as avoiding
resistance to drugs or minimizing
toxicity can be applied to design the
combination therapy.
(Step H) A mouse xenograft model [19] can be
used to study development of
resistance simultaneously.
(Step B revisited) The generated drug combinations are
validated in vitro on the primary
culture.
(Step A revisited) If needed, the circuit is revised or the
drug combination with best response
in vivo (mouse) and in vitro (primary
culture) is then provided to the
patient.
The primary contributions of this paper are: (1) methods
for extraction of numerically relevant drug targets from
single-run drug screens, (2) design of the personalized
TIM circuit based on drug perturbation data, (3) algo-
rithms for sensitivity prediction of a new drug or drug
cocktail, (4) validation over canine osteosarcoma primary
tumors and (5) pathway flow inference using sequen-
tial protein expression measurements. The scope of the
present article is concentrated around steps B, C and D of
Figure 1.
The perturbation data required for our proposed
method originates from a drug screen consisting of 60
small molecule inhibitors with quantified kinase interac-
tion behaviors. This drug screen, denoted Drug Screen
Version 1.0, consists of two sets of data: (i) The first set is
the experimentally generated drug sensitivities provided
as 50% inhibitory concentration (IC50) values. The IC50
values denote the amount of a drug required to reduce
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the population of cancerous cells in vitro by half. The sen-
sitivity values are expected to change during each new
cell line/ tumor culture experiment. The generation of the
sensitivities in step C can be done within 72 hours of ini-
tial biopsy using drug sensitivity assays which is a period
of limited cell divisions for most primary cultures. Thus,
the estimated personalized maps may be closer to real-
time circuits in cancer cells - akin to the signaling found in
an untreated patient within a day or two after biopsy, and
not the evolving consensus pattern of signaling for grow-
ing and dividing tumor cells as subpopulations emerge
with increased fitness in vitro. (ii) In addition, the drug
screen contains experimentally derived half-maximal con-
centration (EC50) values for the interaction of each drug
and each kinase target. The EC50 value is directly related
to the notion of inhibition of a kinase target; in par-
ticular, the EC50 values correspond to the amount of a
compound needed to deactivate via phosphorylation 50%
of the population of the associated target. Hence, for a
drug compound, a target with a lower EC50 is the one
that will be heavily inhibited at low drug concentration
levels. Thus, low EC50 targets are often considered to
be the primary targets of a drug. The remaining targets
are considered to be the side targets of a drug, and are
often ignored. The utility of this EC50 data is its consis-
tency throughout experiments; the EC50 values as curated
from literature searches [16,20] are fixed, regardless of
change of tumor type or patient of origin. This provides
a great amount of prior information for analysis of the
drug screen results, and its usage is supported from the
experiments performed in [17].
The overall goal of the methods presented in this paper
is to create an input-output mathematical framework for
the analysis of and inference on the functional data gen-
erated by the drug screens for the purpose of anti-cancer
drug sensitivity prediction and inference of personalized
tumor survival pathway. The personalized tumor survival
pathway refers to the visual circuit diagram generated
from the inferred Target Inhibition Map as explained in
the methods section. Note that the circuit corresponding
to a TIM is only a coarse representation of the TIM for
visual understanding of the most probable target combi-
nations whose inhibition can reduce the tumor survival.
Since the experiments were conducted on in-vitro cell
cultures with the output being cell viability measured in
terms of IC50, the survival here refers to tumor cell culture
survival and not the overall survival of the patient.
Results
TIM Generation for canine osteosarcoma tumor cultures
and cross-validation estimates of prediction accuracy
The sensitivity prediction and circuit analysis performed
on actual biological data are validations of the proposed
methodology to be described in theMethods section. The
experimental data on four tumor cultures and 60 targeted
drug screen panel were generated in the Keller laboratory
at OHSU.
The cell lines applied to the drug screen were four
canine osteosarcoma cell lines cultured from four distinct
canines, denoted Bailey, Charley, Sy, and Cora. The tumor
cultures were collected by Dr. Bernard Seguin of Oregon
State University from canines that are part of an ongo-
ing clinical trial for osteosarcoma (OSU IACUC approval
numbers for this study are 4217 and 4273). The tumor
samples were collected from client-owned animals that
have developed the disease naturally. All procedures per-
formed on these animals with regards to tumor collection
were strictly for treatment purposes and nothing was done
different because of the drug perturbation study. All pro-
cedures were performed according to standard of care
regardless of whether an animal had its tumor sampled.
For the generation of the experimental data, the canine
osteosarcoma primary cell cultures were plated in 384
well plates at a seeding density of 2000 cells per well
over graded concentrations of 60 small-molecule kinase
inhibitors. Each inhibitor was plated individually at four
concentrations predicted to bracket the IC50 for that drug.
Cells were cultured in RPMI 1640 supplemented with
2mMglutamine, 2mM sodiumpyruvate, 2mMHEPES, 1%
penicillin streptomycin, and 10% fetal bovine serum for 72
hours. At the end of the 72 hour incubation, cell viability
was assessed using theMTS assay. All values were normal-
ized to the mean of seven wells on each plate containing
no drug. The IC50 for each drug was then determined by
identification of the two concentrations bracketing 50%
cell viability and application of the following formula:
[ ((A − 50)/(A − B)) ∗ (DB − DA)]+DA where cell viabil-
ity value above 50% = A (drug dose for this value is DA)
and cell viability value below 50% = B (drug dose for this
value isDB). The experimentally generated IC50 values are
included as Additional file 2. The experimentally gener-
ated sensitivities (in terms of IC50 values) of the 60 drugs
are then scaled to values between 0 and 1.
Among the 60 drugs on the drug screen, 46 drugs have
known target inhibition profiles; of these 46 drugs, 2 pro-
vide information only on the target mTOR (mammalian
target of Rapamycin) and analysis of these drugs are triv-
ial. Thus, the remaining 44 drugs are used to generate the
TIMs. These target profiles were extracted from several
literature sources ([16,20]) based on experimental quan-
titative dissociation constants (kd) which are treated as
EC50 values (explained in the next section) for each drug
across kinase target assays with more than 300 targets.
The target profiles of the drugs are shown in Additional
file 3. Figures 2 and 3 represent the equivalent TIM cir-
cuits generated from experimental data for Bailey and Sy
respectively. The TIM circuits for Charley and Cora are
included in Additional file 1.
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Figure 2 TIM circuit for osteosarcoma primary culture bailey.
To emphasize the biological relevance provided by the
TIM framework employed in the analysis of the biologi-
cal data, we present a more in-depth analysis of the TIM
circuit devised for the canine patient Bailey (shown in
Figure 2). The vast majority of human osteosarcomas con-
tain genetic or post-translational abnormalities in one or
both of the tumor suppressors p53 [21-23] and pRb [24].
The first target identified in this circuit is PKC alpha
(PRKCA). PKC alpha modifies CDKN1A (p21), which is
the primary mediator of p53 tumor suppressor activity
[25]. PSMB5 represents the proteasome (specifically the
beta 5 subunit). Previous studies [26] and early preclinical
data from the Keller laboratory confirms in vitro sensitiv-
ity of many osteosarcomas to proteasome inhibitors and
this sensitivity is hypothesized to be due to the integral
role of the proteasome in p53 regulation [27]. Interest-
ingly, CDK4 is also prominent in this circuit, which is a
primary inhibitor of the tumor suppressor pRb, which is
also frequently abnormal in spontaneous human osteosar-
coma [24]. CDK2 is an important modifier of both p53
and pRb and is also represented in this circuit [28]. The
importance of PI3K pathway in osteosarcoma has also
been recently reported using high throughput genotyping
[29]. Our TIM circuit includes AKT2 which is down-
stream of PI3K [30]. Also, EDNRA selected in the circuit
has been known to interact with PKC and activate ERK
signaling [31].
If the circuit models shown in Figures 2 and 3 are used
to predict sensitivities for comparison with experimen-
tally generated data, we will get optimistic results as the
models are trained using the entirety of the available data.
Thus, we utilize Leave One Out (LOO) and 10-fold Cross
Validation (10-fold CV) approaches to test the validity of
the TIM framework that we present in this paper. For the
LOO approach, a single drug among the 44 drugs with
known inhibition profiles is removed from the dataset and
a TIM is built, using the SFFS suboptimal search algo-
rithm, from the remaining drugs. The resulting TIM is
then used to predict the sensitivity of the withheld drug.
The predicted sensitivity value is then compared to it’s
experimental value; the LOO error for each drug is the
absolute value of the experimental sensitivity y minus
the predicted sensitivity (y′|TIM), i.e. |y − (y′|TIM)|. The
closer the predicted value is to the experimentally gener-
ated sensitivity, the lower the error for the withheld drug.
Tables 1, 2, 3 and 4 provides the complete LOO error
tables and the average LOO error (Mean Absolute Error:
MAE) for each primary culture. The average LOO error
over the 4 cell cultures is 0.045 or 4.5%. For the 10-fold
cross validation error estimate, we divided the available
drugs into 10 random sets of similar size and the testing
is done on each fold while being trained on the remain-
ing 9 folds. This is repeated 10 times and average error
calculated on the testing samples. We again repeated this
experiment 5 times and the average of those mean abso-
lute errors for the primary cell cultures are shown in
Table 5. The detailed results of the 10-fold cross valida-
tion error analysis are included in Additional file 4. We
note that both 10-fold CV and LOO estimates for all the
cultures have errors less than 9%, which is extremely low,
especially considering the still experimental nature of the
drug screening process performed in the Keller laboratory
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Figure 3 TIM circuit for osteosarcoma primary culture Sy.
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Table 1 Leave one out error table for osteosarcoma
primary culture bailey







Bortezomib 0.00 0.00 0.00
Bosutinib (SKI-606) 0.02 0.27 0.29
Dasatinib 0.00 0.91 0.91







PI-103 0.00 0.00 0.00
Sorafenib 0.00 0.00 0.00

















Carfilzomib 0.36 0.64 1.00
Imatinib 0.02 0.21 0.19
BIX 01294 0.18 0.65 0.83
BMS-754807 0.00 1.00 1.00










Lapatinib 0.00 0.00 0.00
Sunitinib 0.01 0.19 0.20




Enzastaurin 0.36 0.64 1.00
PD0332991 0.36 0.64 1.00
Valproate 0.00 0.00 0.00
Resveratrol 0.00 0.00 0.00
Table 1 Leave one out error table for osteosarcoma








BIX 02188 0.00 0.00 0.00
RO4929097 0.00 0.00 0.00
Curcumin 0.00 1.00 1.00
Sodium butyrate 0.00 0.00 0.00
GANT61 0.11 0.58 0.47
Aurothiomalate 0.00 0.00 0.00
(OSI-906) 0.00 0.00 0.00
Pelitinib (EKB-569) 0.03 0.91 0.88
Pred. Sens. = Predicted Sensitivity, Exp. Sens. = Experimental Sensitivity, Error =
|Pred. Sens. − Exp. Sens.|, Avg Err = Average of the 44 leave one out Errors.
and the available response of only 44 drugs with known
target inhibition profile.
To provide a measure of the overlap between drugs, we
considered a similarity measure (D1,D2) based on the
EC50 of the drugs D1 and D2. Let the EC50′s of the drugs
D1 and D2 be given by the n-length vectors E1 and E2
where n denotes the number of drug targets. The entries
for the targets that are not inhibited by the drugs (i.e. no
EC50 value available) are set to 0. Let the vectors V1 and
V2 represent the binarized targets of the drugs i.e. it has a
value of 1 if the target is inhibited by the drug and a value
of zero if the target is not inhibited by the drug. Then, we
define the similarity measure  as:
(D1,D2) =
∑n
i=1min(E1(i),E2(i)) ∗ V1(i) ∗ V2(i)∑n
i=1max(E1(i),E2(i))
(1)
Note that (D1,D1) = 1 and similarity between drugs
with no overlapping targets is zero. If two drugs have
50% targets overlapping with same EC50′s, then the sim-
ilarity measure is 0.5. The similarities between the drugs
are shown in Additional file 5. Note that except two
drugs Rapamycin and Temsirolimus that have a similar-
ity measure of 0.989, all other drugs have significantly
lower similarities with each other. The maximum simi-
larity between two different drugs (other than Rapamycin
and Temsirolimus) is 0.169. This shows that any two
drugs in the drug screen are not significantly overlapping
and the prediction algorithm is still able to predict the
response.
The low error rate illustrates the accuracy and effec-
tiveness of this novel method of modeling and sensitivity
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Table 2 Leave one out error table for osteosarcoma
primary culture charley







Bortezomib 0.00 0.00 0.00
Bosutinib (SKI-606) 0.00 0.00 0.00
Dasatinib 0.02 0.94 0.96







PI-103 0.00 0.00 0.00
Sorafenib 0.00 0.00 0.00

















Carfilzomib 0.33 0.67 1.00
Imatinib 0.00 0.00 0.00
BIX 01294 0.18 0.68 0.86
BMS-754807 0.00 1.00 1.00










Lapatinib 0.00 0.00 0.00
Sunitinib 0.05 0.88 0.82




Enzastaurin 0.00 0.00 0.00
PD0332991 0.00 0.00 0.00
Valproate 0.00 0.00 0.00
Resveratrol 0.00 0.00 0.00
Table 2 Leave one out error table for osteosarcoma








BIX 02188 0.00 1.00 1.00
RO4929097 0.00 0.00 0.00
Curcumin 0.00 1.00 1.00
Sodium butyrate 0.00 0.00 0.00
GANT61 0.57 0.43 1.00
Aurothiomalate 0.00 0.00 0.00
(OSI-906) 0.00 1.00 1.00
Pelitinib (EKB-569) 0.00 1.00 1.00
Pred. Sens. = Predicted Sensitivity, Exp. Sens. = Experimental Sensitivity, Error =
|Pred. Sens. − Exp. Sens.|, Avg Err = Average of the 44 leave one out Errors.
prediction. Furthermore, these error rates are signifi-
cantly lower than those of any other sensitivity predic-
tion methodology we have found. Consistent with the
analysis in [17], the sensitivity prediction rates improve
dramatically when incorporating more information about
drug-protein interaction. To more effectively compare
the results generated via the TIM framework with the
results in [15], we also present the correlation coefficients
between the predicted and experimental drug sensitivity
values in Table 6. The correlation coefficients for pre-
dicted and experimentally generated sensitivities for 24
drugs and more than 500 cell lines ranges from 0.1 to 0.8
when genomic characterizations are used to predict the
drug sensitivities in the CCLE study [15]. In comparison,
our approach based on sensitivity data on training set of
drugs and drug-protein interaction information produced
correlation coefficients > 0.92 (Table 6) for both leave
one out (LOO) and 10-fold cross validation (10-fold CV)
approaches for error estimation.
It should be noted that the sensitivity prediction is per-
formed in a continuous manner, not discretely, and thus
effective dosage levels can be inferred from the predic-
tionsmade from the TIM. This shows that the TIM frame-
work is capable of predicting the sensitivity to anti-cancer
targeted drugs outside the training set, and as such is
viable as a basis for a solution to the complicated problem
of sensitivity prediction.
In addition, we tested the TIM framework using syn-
thetic data generated from a subsection of a human cancer
pathway taken from the KEGG database [32]. Here, the
objective is to show that the proposed TIMmethod gener-
atesmodels that highly represent the underlying biological
network which was sampled via synthetic drug pertur-
bation data. This experiment replicates in synthesis the
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Table 3 Leave one out error table for osteosarcoma
primary culture cora







Bortezomib 0.01 1.00 0.99
Bosutinib (SKI-606) 0.00 0.00 0.00
Dasatinib 0.03 0.83 0.85







PI-103 0.00 0.00 0.00
Sorafenib 0.00 0.00 0.00

















Carfilzomib 0.01 0.99 1.00
Imatinib 0.00 0.00 0.00
BIX 01294 0.23 1.00 0.89
BMS-754807 0.00 1.00 1.00










Lapatinib 0.00 0.00 0.00
Sunitinib 0.02 0.78 0.76




Enzastaurin 0.00 0.00 0.00
PD0332991 0.24 0.76 1.00
Valproate 0.00 0.00 0.00
Resveratrol 0.00 0.00 0.00
Table 3 Leave one out error table for osteosarcoma








BIX 02188 0.03 0.92 0.89
RO4929097 0.00 0.00 0.00
Curcumin 0.00 0.00 0.00
Sodium butyrate 0.00 0.00 0.00
GANT61 0.00 0.00 0.00
Aurothiomalate 0.00 0.00 0.00
(OSI-906) 0.11 1.00 0.89
Pelitinib (EKB-569) 0.01 0.62 0.63
Pred. Sens. = Predicted Sensitivity, Exp. Sens. = Experimental Sensitivity, Error =
|Pred. Sens. − Exp. Sens.|, Avg Err = Average of the 44 leave one out Errors.
actual biological experiments performed at the Keller lab-
oratory at OHSU. To utilize the TIM algorithm, a panel of
60 targeted drugs pulled from a library of 1000 is used as a
training panel to sample the randomly generated network.
Additionally, a panel of 40 drugs is drawn from the library
to serve as a test panel. The training panel and the testing
panel have no drugs in common. Each of the 60 train-
ing drugs is applied to the network, and the sensitivity for
each drug is recorded. The generated TIM is then sam-
pled using the test panel which determines the predicted
sensitivities of the test panel. The synthetic experiments
were performed for 40 randomly generated cancer sub-
networks for each of n = 6, · · · , 10 active targets in the
network. The active targets are those which, when inhib-
ited, may have some effect on the cancer downstream. To
more accurately mimic the Boolean nature of the biolog-
ical networks, a drug which does not satisfy any of the
Boolean network equations will have sensitivity 0, a drug
which satisfies at least one network equationwill have sen-
sitivity 1. The inhibition profile of the test drugs is used to
predict the sensitivity (0 or 1) of the new drug. The average
number of correctly predicted drugs for each n is reported
in Table 7. This synthetic modeling approach generally
produces respectable levels of accuracy, with accuracies
ranging from 89% to 99%. 60 drugs for training mimics the
drug screen setup used by our collaborators and testing
20 drugs for predicted sensitivity approximates a sec-
ondary drug screen to pinpoint optimal therapies. The
performance of the synthetic data shows fairly high relia-
bility of the predictions made by the TIM approach.
We have also tested our algorithm on another set of ran-
domly generated synthetic pathways. The detailed results
of the experiment are included in Additional file 1. A large
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Table 4 Leave one out error table for osteosarcoma
primary culture Sy







Bortezomib 0.00 0.00 0.00
Bosutinib (SKI-606) 0.00 0.59 0.59
Dasatinib 0.01 0.63 0.62







PI-103 0.00 0.00 0.00
Sorafenib 0.00 0.00 0.00

















Carfilzomib 0.38 0.62 1.00
Imatinib 0.00 0.00 0.00
BIX 01294 0.20 1.00 0.82
BMS-754807 0.01 0.53 0.54










Lapatinib 0.00 0.00 0.00
Sunitinib 0.02 0.60 0.58




Enzastaurin 0.00 0.00 0.00
PD0332991 0.05 0.62 0.67
Valproate 0.00 0.00 0.00
Resveratrol 0.00 0.00 0.00
Table 4 Leave one out error table for osteosarcoma








BIX 02188 0.00 0.00 0.00
RO4929097 0.00 0.00 0.00
Curcumin 0.00 0.00 0.00
Sodium butyrate 0.00 0.00 0.00
GANT61 0.38 0.31 0.69
Aurothiomalate 0.00 0.00 0.00
(OSI-906) 0.47 0.53 1.00
Pelitinib (EKB-569) 0.00 0.00 0.00
Pred. Sens. = Predicted Sensitivity, Exp. Sens. = Experimental Sensitivity, Error =
|Pred. Sens. − Exp. Sens.|, Avg Err = Average of the 44 leave one out Errors.
number of testing samples were used for each pathway
prediction and the results indicate an average error of less
than 10% for multiple scenarios. In comparison, the aver-
age error with random predictions was 44%. The average
correlation coefficient of the prediction to actual sensi-
tivity for the 8 sets of experiments (each including 10 or
25 different pathways) was 0.91. The average correlation
coefficient with random predictions was 0. We also report
the standard deviation of the errors and for a representa-
tive example, the 10 percentile of the error was -0.154 and
90 percentile 0.051, thus the 80% prediction interval for
prediction μ was [μ − 0.154 μ + 0.051].
The results of the synthetic experiments on different
randomly generated pathways shows that the approach
presented in the paper is able to utilize a small set of
training drugs from all possible drugs to generate a high
accuracy predictive model.
Methods
In this section, we provide an overview of the model
design and inference from drug perturbation data for
personalized therapy.
Table 5 Cross validation results





The 10 fold- cross valdiation error estimates were calculated for 5 runs and the
average mean absolute error (MAE) across all the drugs is shown.
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Table 6 Correlation coefficients of predicted sensitivities
vs. experimental sensitivities





ρ LOO = Average Pearson Correlation Coefficient for test samples selected
based on Leave One Out approach, ρ 10-fold CV = Average Pearson Correlation
Coefficient for test samples selected based on 10 fold cross validation approach.
Mathematical formulation
Let us consider that we have drug IC50 data for a new pri-
mary tumor after application of m drugs in a controlled
drug screen. Let the knownmulti-target inhibiting sets for
these drugs be denoted by S1, S2,...,Sm obtained from drug
inhibition studies [16,20,33].
The elements of set Si are ei = [ ei,1, ei,2, · · · , ei,n] for i =
1, 2, · · · ,m, where ei,j are real-valued elements describing
the interaction of Si with K = [ k1, k2, · · · , kn], the set of all
kinase targets included in the drug screen. The ei,j’s refer
to the EC50 values discussed previously. It should be noted
that for all Si, ei,j will most often be blank or an extremely
high number denoting no interaction.
The initial problem we wish to solve is to identify the
minimal subset of K, the set of all tyrosine kinase targets
inhibited by them drugs in the drug panel, which explains
numerically the various responses of them drugs. Denote
this minimal subset of K as T. The rationale behind mini-
mization of T is twofold. First, as with any classification or
prediction problem, a primary goal is avoidance of overfit-
ting. Secondly, by minimizing the cardinality of the target
set required to explain the drug sensitivities found in the
exploratory drug screen, the targets included have sup-
portable numerical relevance increasing the likelihood of
biological relevance. Additional targets may increase the
cohesiveness of the biological story of the tumor, but will
not have numerical evidence as support. This set T will be
the basis of our predictive model approach to sensitivity
prediction.
Table 7 Results of synthetic experiments based on KEGG
pathways
Targets Correct prediction Accuracy percentage
n = 6 39.83 99.56
n = 7 38.68 96.69
n = 8 38.18 95.44
n = 9 36.80 92.00
n = 10 35.63 89.06
Correct Prediction = Average number of correct prediction for 40 testing drugs
for 40 different synthetic pathways.
Before formulation of the problem for elucidating T,
let us consider the nature of our desired approach to
sensitivity prediction. From the functional data gained
from the drug screen, we wish to generate a personalized
tumor survival pathway model instead of a linear function
approximator with minimal error. We are working under
the fundamental assumption that the tumor survival path-
way is nonlinear in its behavior; this assumption is reason-
able given the difficulty in treating multiple forms of can-
cer. One frequent theory in personalized therapy is that
effective treatment results from applying treatment across
multiple important biological pathways. These pathways
generally consist of sequentially activated gene and pro-
tein nodes acting as a feedback network. Treatment of
individual pathways may not be sufficient for majority of
diseases, so multiple independent parallel pathways must
be targeted to create an effective treatment. We believe
that one possible approach to the analysis of multiple
pathway treatment is to begin with an underlying frame-
work based on the Boolean interactions of the multiple
targets in the pathway architecture. The approach is based
on developing families of Boolean equations that describe
the multiple treatment combinations capable of acting as
an effective intervention strategy. For the initial step of
developing the underlying Boolean functions, an initial
binarization of the data set must be performed. However,
the resulting model lends itself to numerous continuous
approaches to sensitivity prediction which we will explore
further in the paper.
Binarization of drug targets and conversion of IC50′s to
sensitivities
In this subsection, we present algorithms for generation
of binarized drug targets (1 denoting that the target is
inhibited by the drug and 0 denoting that the target is
not modified by the drug) and continuous sensitivity score
of each drug (a number between 0 and 1 with a higher
value denoting that the drug is effective on the tumor).
The inputs for the algorithms in this subsection are the
EC50′s of the drug targets and the IC50′s of the drugs when
applied to a tumor culture.
In order to perform the binarization, we must con-
sider the nature of the data we are given. In particular,
we are provided with an IC50 for each drug (the con-
centration of the drug necessary to eliminate 50% of the
tumor cell population), and an EC50 value for each kinase
target inhibited by the drug. Under the assumption that
the primary mechanism of tumor eradication is, in fact,
the protein kinase inhibition enacted by these targeted
drugs, a natural consequence would be the existence of a
relationship between the IC50 and EC50 values. This rela-
tionship is explained as such: suppose for a drug Si the
IC50 value of Si and the EC50 of kinase target kj, (kj ·ei,j) are
of similar value, then it can be reasonably assumed that
Berlow et al. BMC Bioinformatics 2013, 14:239 Page 11 of 20
http://www.biomedcentral.com/1471-2105/14/239
kinase target kj is possibly a primary mechanism in the
effectiveness of the drug. In other words, if 50% inhibition
of a kinase target directly correlates with 50% of the tumor
cells losing viability, then inhibition of the kinase target is
most likely one of the causes of cell death. Hence, the tar-
get that matches the drug IC50 is binarized as a target hit
for the drug.
The above assumption of direct correlation for all
successful drugs is obviously an extremely restrictive
assumption and will be unable to produce high accu-
racy predictions. Thus, the binarization scheme has to be
modified to incorporate the following three factors:
First: noises in varying magnitude will be present in
the drug screen data generated by our
collaborators. The noise is unavoidable, and as
such, needs to be accounted for. In addition,
despite the high accuracy of the drug-protein
interaction data procured from literature, we
should still account for possible errors in the
EC50 values for the numerous drugs.
Second: the restrictive assumption considers that
effective drugs operate on single points of
failure within the patient’s signaling pathway.
In reality, high sensitivity to a drug is often
attributed to a family of related kinases (such
as the Aurora kinase family) or several
independent kinases working synergistically
over one or multiple pathways to induce tumor
death. This cooperative multivariate behavior
needs to be taken into account while binarizing
a drug to its multiple possible targets.
Third: despite the high level of currently available
knowledge on the biological effects of
numerous targeted drugs, there remains the
possibility of a drug having high sensitivity
while having no known mechanisms explaining
its sensitivity. Therefore, we must consider the
situation where there are latent mechanisms
not considered within the dataset that are
proving to be effective in some combination of
treatment. This point does not necessarily
eliminate the possibility of kinase mechanisms
being an important factor.
We address all three concerns as follows: (1) By consid-
ering the log scaled EC50 values for each target and the
log scaled IC50 value for each drug, we convert the mul-
tiplicative noise to additive noise. In addition, we employ
scalable bounds around the IC50′s to determine binariza-
tion values of the numerous kinase targets for each drug.
The bounds can be scaled to allow targets that may have
EC50′s higher than the IC50 to be considered as a possi-
ble treatment mechanism. (2) We extend the bounds to
low EC50 levels, and often down to 0, to incorporate the
possibility of target collaboration at various different EC50
levels. While a high IC50 indicates the likelihood of drug
side targets as therapeutic mechanisms, it does not pre-
clude the possibility of a joint relationship between a high
EC50 target and a low EC50 target. Hence, to incorporate
the numerous possible effective combinations implied by
the IC50 of an effective drug, the binarization range of tar-
gets for a drug is the range α· log(IC50) ≤ log(EC50) ≤
β · log(IC50) where 0 ≤ α  β . (3) For reliability and
validity of the target set that we aim to construct, it is
important to keep β in a reasonable range, i.e. β should be
a smaller constant such as 3 or 4. For the situation where
the above bounds do not result in at least one binarized
target, the immediate option is to eliminate the drug from
the data set before target selection. This prevents incom-
plete information from affecting the desired target set. As
information concerning the drug screen agents gradually
becomes complete with respect to other forms of data,
such as gene interaction data, additional mechanisms for
unexplained targets can be explored and incorporated
more readily into the predictive model. With binarization
of the data set as explained, we now present the minimiza-
tion problem that produces a numerically relevant set of
targets, T.
Consider the target set T = [T1,T2, · · · ,Tn], where
Ti ∈ {0, 1}. Here, 1 denotes inclusion in the target set T
and 0 denotes exclusion. For any target setT0, one can find
the representation under T0 of each drug Si, i ∈ 1, · · · ,m
as (Si|T0) = [ ei,1 · T1, ei,2 · T2, · · · , ei,n · Tn]. As the T0 will
be the basis of the new representation for each drug, this
will result in n0 columns which will be 0 for all Si, where
n0 is the number of Ti = 0, i.e. the number of targets not
included in T0. The resulting representation of each drug
in T0 is then an n − n0 vector of EC50 values.
While the representation of each drug will change as
the target set T changes, the IC50 values for each of the
m drugs remains the same. These experimental sensitivity
values will be used to test the numerous different target
sets to quantify the strength of the model for any target
set.
To simplify scoring of the target set, we first convert the
IC50 for each drug Si to a continuous-valued sensitivity
score yi ∈ [ 0, 1]
yi =
{
1, if IC50,i < Cmaxi
c ∗ (1 − log(IC50,i)/log(MaxDosei), if Cmax ≤ x ≤ MaxDosei
where MaxDosei is the maximum dose of drug Si given,
Cmaxi is the maximum achievable clinical dose of drug Si,
and c = 1 − log(Cmaxi)/log(MaxDosei) so that the scor-
ing function is continuous. MaxDose is used to prevent
inferences being made on data that is not available. While
it would be possible to attempt interpolation to infer an
IC50 from the multiple available data points, such infer-
ence cannot be fully quantified. Hence, drugs which fail
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to achieve an IC50 within the allotted dosage are given the
score of 0, which means ineffective. The Cmax value is
used to apply a variable score to the numerous drugs based
on the inherent toxicity of the drug. This will also pre-
vent bias towards drugs with low IC50’s; some drugs may
achieve efficacy at higher levels solely based on the drug
EC50 values.
Construction of the relevant target set
In this subsection, we present approaches for selection of a
smaller relevant set of targets T from the set of all possible
targets K. The inputs for the algorithms in this subsection
are the binarized drug targets and continuous sensitivity
score (output of the algorithms from previous subsection).
With the scaled sensitivities, we can develop a fitness
function to evaluate the model strength for an arbitrary
set of targets. As has been established, for any set of
targets T0, drug Si has a unique representation (Si|T0).
This representation can be used to separate the drugs
into different bins based on the targets it inhibits under
T0. Within each of these bins will be several drugs with
identical target profiles but different scaled scores. Let
the set of scores in each bin be denoted Y (Sj|T0) for Sj
in an arbitrary bin, and we will assign to each bin the
mean sensitivity score of the bin, E(Y (Sj|T0)). Denote
this value P(Sj|T0). Within each bin, we want to mini-
mize the variation between the predicted sensitivity for
the target combination, P(Sj|T0), and the experimental
sensitivities, Y (Sj|T0). This notion is equivalent to mini-
mizing the inconsistencies of the experimental sensitivity
values with respect to the predicted sensitivity values for
all known target combinations for any set of targets, which
in turn suggests the selected target set effectively explains
the mechanisms by which the effective drugs are able
to kill cancerous cells. Numerically, we can calculate the




|P(Sj|T0) − Y (Sj|T0)| (2)
This analysis has one notable flaw: if we attempt to
only separate the various drugs into bins based on inter-
bin sensitivity error, we can create an over-fitted solution
by breaking each drug into an individual bin. We take
two steps to avoid this. First, we attempt to minimize the
number of targets during construction of T0. Second, we
incorporate an inconsistency term to account for target
behavior that we consider to be biologically inaccurate.
To expand on the above point, we consider there are
two complementary rules by which kinase targets behave.
Research has shown that the bulk of viable kinase tar-
gets behave as tumor promoters, proteins whose presence
and lack of inhibition is related to the continued survival
and growth of a cancerous tumor. These targets essentially
have a positive correlation with cancer progression. This
is in opposition to tumor suppressors, proteins that have
been shown to have a negative correlation with the devel-
opment of cancer. To capture the behavior of oncogenes,
we partially formulate our problem on two rules [34]:
Rule 1: If (Si|T0) is the inhibiting set of targets for drug
i and the drug is successful in inhibiting the
circuit, then any set B such that Si ⊂ B will also
be successful in inhibiting the circuit.
Rule 2: If (Si|T0) is the inhibiting set of targets for drug
i and the drug is unsuccessful in inhibiting the
circuit, then any set B such that B ⊂ Si will also
be unsuccessful in inhibiting the circuit.
Rule 1 essentially says that if inhibiting a number of target
proteins has blocked signaling pathways, then inhibiting
more target proteins will not open any path that has
already been blocked. Rule 2 captures the fact that if a set
of target protein inhibitors is unsuccessful in blocking the
paths of a circuit, then any reduced number of target pro-
tein inhibitors among the inhibiting proteins cannot block
all the paths.
The above rules assume that the kinases in focus are
oncogenes, genes that promote cancer growth and whose
inhibition can prevent tumor development. The majority
of kinases in the Drug Screen panel behave as oncogenes,
and as such, our approach utilizes the above rules.
Target sets resulting in combination scores that do not
follow the rule-based behavior incur an inconsistency




χ(bin, drug)|P(Sj|T0) − Y (Sj|T0)| (3)
where χ(·) is the indicator function which is 1 when the
experimental drug score is inconsistent with the predicted
subset/superset bin score.
We now present the complete target set score, and as













χ(bin, drug)|P(Sj|T0) − Y (Sj|T0)| (4)











|P(Sj|T) − Y (Sj|T)|
+ χ(bin, drug)|P(Sj|T) − Y (Sj|T)|) (5)
For brevity, we will denote the scoring function of a target
set with respect to the binarized EC50 values S and the
scaled sensitivity scores Y, (T ; S,Y ). As the S and Y sets
will be fixed when target set generation begins, we reduce
this notation further to (T).
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Note that T ⊆ K where K denotes the set of all possible
targets. 2|K | is the total number of possibilities forT which
is extremely huge and thus prohibits exhaustive search.
Thus the inherently nonlinear and computational inten-
sive target set selection optimization will be approached
through suboptimal search methodologies. A number of
methods can be applied in this scenario and we have
employed Sequential Floating Forward Search (SFFS) [35]
to build the target sets. We selected SFFS as it generally
has fast convergence rates while simultaneously allowing
for a large search space within a short runtime. Addition-
ally, it naturally incorporates the desired target set mini-
mization aim as SFFS will not add features that provide no
benefit. We present the SFFS algorithm for construction
of the minimizing target set in algorithm 1.
Algorithm 1 SFFS Algorithm for generating relevant
Target Sets
Inputs: S = {Si|i ∈ {1, · · · ,m}}, the binarized set of
drug-protein EC50 values
Y = {yi|i ∈ {1, · · · ,m}}, the scaled drug
sensitivities
Output: T, Relevant Target Set
 = zeros(N + 1)
(0) = ∞
count = 0
T = { }
x1 = argminx∈K\T {(T ∪ x)}
while (T ∪ x1) < (count) do
T = T ∪ x1
count = count + 1
(count) = (T)
x2 = argminx∈T {(T \ x)}
while (T \ {x2}) < (count − 1) do
T = T \ {x2}
(count − 1) = (T)
count = count − 1
x2 = argminx∈T {(T \ x)}
end while
x1 = argminx∈K\T {(T ∪ x)}
end while
return T
Complexity of target set generation
The algorithm to generate the error score given a tar-
get set T is of order O(m2), quadratic with respect to
the number of drugs. In general, the number of drugs
remains relatively low. The SFFS algorithm has a single
step runtime of |K |, making it linearly increasing with the
number of kinase targets. This number is often approx-
imately 300. The total computational cost of selecting a
minimizing target set isO(|K |·m2). It should be noted this
algorithm is extremely parallelizable, and as such adding
additional processors allows the effect of the addition of
the numerous kinase targets to be computed significantly
faster.
Target combination sensitivity inference from a selected
target set
In this subsection, we present algorithms for prediction
of drug sensitivities when the binarized targets of the test
drugs are provided. The inputs for the algorithms in this
subsection are the binarized drug targets, drug sensitiv-
ity score and the set of relevant targets for the training
drugs.
Construction of the target set that solves Eq. 5 pro-
vides information concerning numerically relevant targets
based on the drug screen data. However, the resulting
model is still limited in its amount of information. Given
the binning behavior of the target selection algorithm,
the predicted sensitivity values will include only those
for which experimental data is provided, and again only
a subset of those target combinations. Hence, in order
to expand the current model from one of explanation to
one that includes prediction, inferential steps have to be
applied using the available information.
The first step in inference is prediction of sensitivity val-
ues for target combinations outside the known dataset.
Consider that the set of drug representations, (S|T), con-
sists of c unique elements. In addition, the number of
targets added to the minimizing target set is |T | = n.
The total possible target combinations is then 2n for bina-
rized target inhibition, and there are thus 2n − c unknown
target combination sensitivities. We would like to be able
to perform inference on any of the 2n − c unknown sen-
sitivity combination, and we would like to utilize known
sensitivities whenever possible.
To begin the inference step, let us first recall the 2 com-
plementary rules for kinase target behavior upon which
we base this model.
Rule 1: If (Si|T) is the inhibiting set of targets for drug
i and the drug is successful in inhibiting the circuit, then
any set B such that Si ⊂ B will also be successful in
inhibiting the circuit.
Rule 2: If (Si|T) is the inhibiting set of targets for drug i
and the drug is unsuccessful in inhibiting the circuit, then
any set B such that B ⊂ Si will also be unsuccessful in
inhibiting the circuit.
We consider a third rule that expresses target combi-
nation behavior as a function of its most similar target
combinations.
Rule 3: If (Ci|T) is the inhibiting set of a target com-
bination with unknown sensitivity, then the sensitivity of
(Ci|T) will be at least that of (Ci|T)’s closest subsets and
will be at most (Ci|T)’s closest supersets.
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Rule 3 follows from the first two rules; rule 1 provides
that any superset will have greater sensitivity, and rule 2
provides that any subset will have lower sensitivity.
To apply rule 3 in practical situations, we must guaran-
tee that every combination (Ci|T) will have a subset and
superset with an experimental value. We will assume that
the target combination that inhibits all targets in T will
be very effective, and as such will have sensitivity 1. In
addition, the target combination that consists of no inhi-
bition of any target, which is essentially equivalent to no
treatment of the disease, will have no effectiveness, and
as such will have a sensitivity of 0. Either of these can be
substituted with experimental sensitivity values that have
the corresponding target combination. In numerous prac-
tical scenarios, the target combination of no inhibition has
sensitivity 0.
With the lower and upper bound of the target combi-
nation sensitivity fixed, we now must perform the infer-
ence step by predicting, based on the distance between
the subset and superset target combinations. We per-
form this inference based on binarized inhibition, as
the inference here is meant to predict the sensitivity
of target combinations with non-specific EC50 values.
Refining sensitivity predictions further based on actual
drugs with specified EC50 values will be considered
later.
Let (Cl|T) = [ k1,l, k2,l, · · · , kn,l] be the target combina-
tion of the subset of (Ci|T) with the highest sensitivity,
and let (Cu|T) = [ k1,u, k2,u, · · · , kn,u], the superset target
combination with the lowest sensitivity. Let the sensitiv-
ity of (Cl|T) and (Cu|T) be yl and yu respectively. Let the
hamming distance between Cl and Cu be h = (Cl|T) ⊕
(Cu|T), and the hamming distance between (Ci|T) and
(Cl|T) be d = (Cl|T) ⊕ (Ci|T). Therefore, to transi-
tion from (Cl|T) to (Ci|T), it will require the inhibition
of an additional d targets, denoted {t1, t2, · · · , td}, and the
remaining h−d, denoted {td+1, · · · , th} targets will remain
uncontrolled. For naive inference, we can consider that
over the course of the addition of the h targets needed
to transition from (Cl|T) to (Cu|T), the change in sensi-
tivity due to the addition of each target is uniform. With
(Cl|T) as the lower bound of the drug sensitivity, the
resulting naive sensitivity from the addition of d2 ≤ h
targets is





where n is a tunable inference discount parameter, where
decreasing n increases yi(d2) and presents an optimistic
estimate of sensitivity.
We can extend the sensitivity inference to a non-naive
approach. Suppose for each target ti ∈ T , we have an asso-
ciated target score αi. The score can be derived from prior
knowledge or pre-modeling analysis. Given this vector
α = [α1,α2, · · · ,αn], we will define yi as follows:
yi({t1, t2, · · · , td}) = yl + (yu − yl)·(
α(t1) + α(t2) + · · · + α(tn)
α(t1) + α(t2) + · · · + α(td) + α(td+1) + · · · + α(th)
)n
(7)
which can be written as






As desired, if the majority of the mass of the weights of
t1, t2, · · · , th rest in t1, t2, · · · , td , the sensitivity of yi will
be close to yu.
With the inference function defined as above, we can
create a prediction for the sensitivity of any binarized
kinase target combination relative to the target set T ; thus
we can infer all of 2n − c unknown sensitivities from the
experimental sensitivities, creating a complete map of the
sensitivities of all possible kinase target-based therapies
relevant for the patient. As noted previously, this complete
set of sensitivity combinations constitutes the TIM. The
TIM effectively captures the variations of target combina-
tion sensitivities across a large target set. However, we also
plan to incorporate inference of the underlying nonlinear
signaling tumor survival pathway that acts as the underly-
ing cause of tumor progression. We address this using the
TIM sensitivity values and the binarized representation of
the drugs with respect to target set, (Si|T0).
Generation of TIM circuits
In this subsection, we present algorithms for inference
of blocks of targets whose inhibition can reduce tumor
survival. The resulting combination of blocks can be rep-
resented as an abstract tumor survival pathway which will
be termed as the TIM circuit. The inputs for this subsec-
tion are the inferred TIM from previous subsection and a
binarization threshold for sensitivity. The output is a TIM
circuit.
Consider that we have generated a target set T for
a sample cultured from a new patient. With the abil-
ity to predict the sensitivity of any target combination,
we would like to use the available information to dis-
cern the underlying tumor survival network. Due to the
nature of the functional data, which is a steady-state snap-
shot and as such does not incorporate changes over time,
we cannot infer models of a dynamic nature. We con-
sider static Boolean relationships. In particular, we expect
two types of Boolean relationships: logical AND relation-
ships where an effective treatment consists of inhibiting
two or more targets simultaneously, and logical OR rela-
tionships where inhibiting one of two or more sets of
targets will result in an effective treatment. Here, effec-
tiveness is determined by the desired level of sensitivity
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before which a treatment will not be considered satis-
factory. The two Boolean relationships are reflected in
the 2 rules presented previously. By extension, a NOT
relationship would capture the behavior of tumor sup-
pressor targets; this behavior is not directly considered in
this paper. Another possibility is XOR (exclusive or) and
we do not consider it in the current formulation due to
the absence of sufficient evidence for existence of such
behavior at the kinase target inhibition level.
Thus, our underlying network consists of a Boolean
equation with numerous terms. To construct the minimal
Boolean equation that describes the underlying network,
we utilize the concept of TIM presented in the previous
section. Note that generation of the complete TIM would
require 2n − c ≈ 2n inferences. The inferences are of
negligible computation cost, but for a reasonable n, the
number of necessary inferences can become prohibitive as
the TIM is exponential in size. We assume that generat-
ing the complete TIM is computationally infeasible within
the desired time frame to develop treatment strategies for
new patients. Thus, we fix amaximum size for the number
of targets in each target combination to limit the number
of required inference steps. Let this maximum number of
targets considered be M.
We then consider all non-experimental sensitivity com-
binations with fewer than M + 1 targets. As we want
to generate a Boolean equation, we have to binarize the
resulting inferred sensitivities to test whether or not a tar-
get combination is effective. We denote the binarization
threshold for inferred sensitivity values by θ ∈ [ 0, 1]. As
θi → 1, an effective combination becomes more restric-
tive, and the resulting boolean equations will have fewer
effective terms. There is an equivalent term for target
combinations with experimental sensitivity, denoted θe.
We begin with the target combinations with experimen-
tal sensitivities. For converting the target combinations
with experimental sensitivity, we binarize those target
combinations, regardless of the number of targets, where
the sensitivity is greater than θe. The terms that represent
a successful treatment are added to the Boolean equation.
Furthermore, the terms that have sufficient sensitivity
can be verified against the drug representation data to
reduce the error. To find the terms of the network Boolean
equation, we begin with all possible target combinations
of size 1. If the sensitivity of these single targets are suf-
ficient relative to θi and θe, the target is binarized; any
further addition of targets will only improve the sensitivity
as per rule 3. Thus, we can consider this target completed
with respect to the equation, as we have created the mini-
mal term in the equation for the target. If the target is not
binarized at that level, we expand it by including all pos-
sible combinations of two targets including the target in
focus.We continue expanding this method, cutting search
threads once the binarization threshold has been reached.
Algorithm 2 Algorithm for generation of minimal
boolean equation
Inputs: T, the set of kinase targets
M , the maximum number of targets in an inferred
boolean term
θe, θi ∈ [ 0, 1] , the threshold for experimental and
inferred sensitivity binarization
bins, the target bins to separate training drugs




for b ∈ bins do
if sensitivity(b|T) ≥ θe then
Terms = Terms ∪ b
end if
end for
while Queue = ∅ do
n = Pop(Queue)
if sensitivity(n|T) ≥ θi then
Terms = Terms ∪ n
else
if∑ binary(n|T) < M then






for n ∈ Terms do
form ∈ Terms do
if binary(n|T) ⊂ binary(m|T) then





The method essentially resembles a breadth or depth-
first search routine over n branches to a maximum depth
of M. This routine has time complexity of O(D ∗ nM),
and will select the minimal terms in the Boolean equation.
The D term results from the cost of a single inference.
The time complexity of this method is significantly lower
than generation of the complete TIM and optimizing the
resulting TIM to a minimal Boolean equation. For the
minimal Boolean equation generation algorithm shown in
algorithm 2, let the function binary(x|T) return the binary
equivalent of x given the number of targets in T, and
let sensitivity(x|T) return the sensitivity of the inhibition
combination x for the target set T.
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With the minimal Boolean equation created using
Algorithm 2, the terms can be appropriately grouped
to generate an equivalent and more appealing mini-
mal equation. To convey the minimal Boolean equation
to clinicians and researchers unfamiliar with Boolean
equations, we utilize a convenient circuit representation,
as in Figures 2 and 3. These circuits were generated from
two canine subjects with osteosarcoma, as discussed in
the results section.
The circuit diagrams are organized by grouped terms,
which we denote as blocks. Blocks in the TIM circuit act
as possible treatment combinations. The blocks are orga-
nized in a linear OR structure; treatment of any one block
should result in high sensitivity. As such, inhibition of
each target results in its line being broken. When there
are no available paths between the beginning and end of
the circuit, the treatment is considered effective. As such,
each block is essentially a modified AND/OR structure.
Within the blocks, parallel lines denote an AND relation-
ship, and adjacent lines represent an OR relationship. The
goal of an effective treatment then, from the perspective of
the network circuit diagram, is to prevent the tumor from
having a pathway by which it can continue to grow.
Discussion
In this section, we discuss extensions of the TIM frame-
work presented earlier. We provide foundational work
for incorporating sensitivity prediction via continuous-
valued analysis of EC50 values of new drugs as well as
theoretical work concerning dynamical models generated
from the steady state TIMs developed previously.
Incorporating continuous target inhibition values
The analysis considered in the earlier sections was based
on discretized target inhibition i.e. each drug was denoted
by a binary vector (S|T) representing the targets inhibited
by the drug. The framework can predict the sensitivities of
new drugs with high accuracy as illustrated by the results
on canine osteosarcoma tumor cultures. However, the
current framework can also be modified to incorporate
the continuous nature of target inhibition and application
of different concentrations of a new drug. Let us con-
sider that a drug i with target set T0 and EC50 profile
ei,1, ei,2, · · · , ei,n is applied at concentration x nM . For each
EC50 value ei,j, we can fit a hill curve or a logistic func-
tion to estimate the inhibition of target j at concentration
x nM. For instance a logistic function will estimate the
inhibition of target j as f (j|x) = 1/(1 + elog(ei,j/x)). Note
that at concentration x = ei,j , f (j|x) = 0.5 as desired.
This approach can be applied to arrive at a continuous
target profile zi,1, zi,2, · · · , zi,n of a drug that is dependent
on the applied drug concentration. The zi,j’s denote real
numbers between 0 and 1 representing the inhibition ratio
of target j. This approach can also be applied to generate
drug target profiles for a combination of drugs at differ-
ent concentrations. To arrive at the sensitivity prediction
for a new target inhibition profile, we can apply rules sim-
ilar to Rules 1, 2 and 3 along with searching for closest
target inhibition profiles among the training data set. The
block analysis performed using discretized target inhi-
bitions can provide smaller sub-networks to search for
among the target inhibition profiles.
Incorporating network dynamics in the TIM formulation
The TIM developed in the previous sections is able to
predict the steady state behavior of target inhibitor com-
binations but cannot provide us with the dynamics of
the model or the directionality (upstream or downstream)
of the tumor pathways. This limitation is a result of
the experimental drug perturbation data being from the
steady state. Our results show that the proposed approach
is highly successful in locating the primary faults in a
tumor circuit and predict the possible sensitivity of target
combinations at the current time point. However, exten-
sion of this model to incorporate the directional pathways
will require protein or gene expression measurements.
The extension refers to steps F1 and F2 in Figure 1. These
steps are not necessary to design the control policy but if
performed can provide superior performance guarantees.
If we plan to infer a dynamic model from no prior knowl-
edge, the number of required experiments will be huge
and will primarily require time- series gene or protein
expression measurements. In this section, we will show
that the circuit produced by our TIM approach can be
used to significantly reduce the search space of directional
pathways. To arrive at the potential dynamical models sat-
isfying the inferred TIM, we will consider the possible
directional pathways that can generate the inferred TIM
and convert the directional pathways to discrete Boolean
Network (BN) [36] models. The TIM can be used to locate
the feasible mutation patterns and constrain the search
space of the dynamic models generating the TIM. For
the duration of the Network Dynamics analysis, we will
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Figure 4 Feasible dynamical model structures. Two possible
dynamical models of a 3 target system (a) K1 and K2 are activated
due to mutations which in turn activates K3 (b) K3 is activated due to
mutation which in turns activate K1 and K2.
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Directional pathway to BN To generate a discrete
dynamical Boolean Network (BN) model [36] of a direc-
tional pathway, we will first consider the starting muta-
tions or latent activations. The number of states in the BN
will be 2n+1 for n targets. Each state will have n + 1 bits
with first n bits referring to the discrete state of the n tar-
gets and the least significant bit (LSB) will correspond to
the binarized phenotype ie. tumor (1) or normal (0). The
rules of state transition are (a) A target state at time t + 1
becomes 1 if any immediate upstream neighbor has state
1 at time t for OR relationships or all immediate upstream
neighbors have state 1 at time t for AND relationships.
Note that the examples have OR type of relations as they
are the most commonly found relations in biological path-
ways (based on illustrated pathways in KEGG). (b) For
the BN without any drug, the targets that are mutated or
have latent activations will transition to state 1 within one
time step. (c) For a target with no inherent mutation or
latent activation, the state will become 0 at time t + 1 if
the immediate upstream activators of the target has state 0
at time t.
Let us consider the simple example of a biological path-
way shown in Figure4(a). The downstream target K3 can
be activated by either of the upstream targets K1 or K2.
The tumor is in turn caused by the activation of K3.
For this directional pathway, we will assume that K1 and
K2 are activated by their own mutations or have latent
activations. The corresponding BN transition diagram
for this pathway is shown in Figure 5. For instance, if
we consider the state 0010 at time t, it denotes K1, K2
being inactive and K3 being active and the phenotype
being non-tumorous. Based on the directional pathway
in Figure 4(a), activation of K3 causes tumor and thus
the phenotype will change to tumor (i.e. 1) at t + 1.
We are given that only K1 and K2 have mutations or
latent activations, thus the activation K3 cannot be main-
tained without the activation of either K1 or K2 and
thus we will have K3 = 0 at t + 1. However, since K1
and K2 have mutations or latent activations, they will
become 1 at time t + 1 which in turn will activate K3 at
time t + 2.










Figure 5 State transitions of the BN for the directional pathway
in Figure 4(a).
Dynamical model following target inhibition The BN
in Figure 5 can also be represented by a 16× 16 transition
matrix Q representing the state transitions. To generate
the dynamic model after inhibition of a specific target
set S1 (by application of targeted drugs), we should con-
sider that the transition i → j in the un-treated system
will be converted to i → z in the treated system where
z differs from j only in the target set S1 and all targets
in S1 have value 0 for z. Each target inhibition combina-
tion can be considered as multiplying a matrix Tc to the
initial transition matrix Q. Each row of Tc contains only
one non-zero element of 1 based on how the inhibition
alters the state. If we consider n targets, n Tc’s in combi-
nation can produce a total of 2n possible transformation
matrices T1,T2, · · · ,T2n . The TIM denotes the state of
the LSB of the attractor for the 2n transition matrices
T1Q,T2Q, · · · ,T2nQ starting from initial state 11 · · · 1 (i.e.
all targets considered in the TIM and tumor are activated).
For instance, if we consider that our drug inhibits the
target K3 (i.e. set S1 = {K3}), the discrete dynamic model
following application of the drug is shown in Figure 6. We
should note that the equilibrium state of the network 1100
has 0 for the tumor state. This is because the tumor is
activated by K3 and inhibition of K3 should eradicate the
tumor. On the other hand, since both K1 and K2 can cause
tumor through activation of intermediate K3, inhibition of
only one of K1 and K2 will not block the tumor. The BN
following inhibition of K2 is shown in Figure 7 where the
attractor 1011 denotes a tumorous phenotype.
Experiment design to infer the dynamic pathway
structure The TIM can be used to produce possible
dynamic models based on assumptions of latent activa-
tions or mutations. For instance, knowledge of the steady-
state value of the target K1 following application of target
inhibitor for K3, will remove one of the possibilities. Fol-
lowing inhibition of K3, the value of K1 will remain 1 for
the case of Figure 4(a) as K1 is upstream of K3. Conversely,
the value of K1 will be 0 for the second case as K3 activates
K1.
In the following paragraphs, we will consider a gen-
eral pathway obtained from a TIM having the structure
shown in Figure 8 but with unknown directionalities of
the blocks and target positions. For the current analy-
sis, we will assume that there are no common targets
0000 1001 







Figure 6 BN state transition following inhibition of target K3.
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Figure 7 BN state transitions following inhibition of target K2.
in distinct blocks. We will consider that the pathway
has L blocks in series (B1,B2, · · · ,BL) and each block Bi
has ai parallel lines with each line j containing bij targets






Assuming that the n targets are distinct, the maximum





j=1(bij)!. Each parallel line j in block
i can have bij ! possible directional orientations.
If the Figure 8 represents a possible directional orien-
tation, then only the targets K11,1,K12,1 · · ·K1a1,1 will have
initial activations due to mutations or latent activations.
Some other downstream target cannot have a mutation or
latent activation otherwise the target inhibition combina-
tion K11,1,K12,1 · · ·K1a1,1 will not be effective.
For our analysis, we are assuming that we can inhibit
specific targets of our choice and we can measure the
steady state target expression following application of the
target inhibitions.
We can locate the directionality of the blocks B1 to BL
by using at most L − 1 steady state measurements. We
can start by randomly picking any block Bi and blocking
the targets in that block, the blocks that will remain acti-
vated will be upstream of that block and the blocks that
   
,  ,  
,  ,   
Figure 8 A general abstract pathway resulting from a target
inhibition map.
will be deactivated following the inhibition of block Bi will
be located down-stream of Bi.
Note that the number of experiments required is based
on steady state measurements following particular per-
turbations. Time series measurements can reduce the
number of experiments required but may not be always
technically feasible.
The expected number of experiments required to detect
the directionality of L serial blocks is
2L − 1
3 for L ≥ 2 (9)
The next step will be locating the directionality of tar-
gets in each parallel line of the block. We can start with
an experiment where for each block Bi, one target from
each line up to a maximum of ai − 1 lines will be inhib-
ited. We cannot inhibit all the lines in a block or else the
downstream blocks will also be inhibited and no infer-
ence can be made on those blocks for that experiment.
While locating the directionality of the serial blocks Bi, we
have already validated the position of one target from each
parallel line in a serial block.
If we consider a single block Bi, each experiment can
detect the location of ai − 1 targets, thus the total
number of experiments required to decipher the pos-
sible directionalities of the targets in the block Bi is





ai−1  − 1) where Si ={1, · · · , ai}.
Thus for the overall map, the worst case number of
experiments NwE required to decipher the directionalities
of all the targets is upper-bounded by








ai − 1  −˘1)} + L − 1 (10)
where S = {1, · · · , L}. Utilizing equation 9, the expected
number of experimentsNaE required to decipher the direc-
tionalities of all the targets is upper-bounded by












In this article, we presented a novel framework for pre-
dicting the effectiveness of molecularly targeted drugs.
We used drug perturbation data to generate a map of
the underlying genetic regulatory pathway. Using actual
experimental data, we were able to show the effectiveness
of our approach for drug sensitivity prediction. The pro-
posed TIM approach produced a low average leave one
Berlow et al. BMC Bioinformatics 2013, 14:239 Page 19 of 20
http://www.biomedcentral.com/1471-2105/14/239
out cross validation error of 5% when applied to pertur-
bation data generated from four primary canine tumors
using a set of 60 drugs. We should note that the cur-
rent 60 drug screen is a small one and technology has
been developed for drug screens with a far greater number
of drugs. We are currently experimenting with pharma-
ceutical drug library consisting of more than 300 small
molecule inhibitors. We expect that the use of larger
number of drugs will increase the accuracy further and
generate maps with greater robustness. The scope of the
present article is concentrated around steps B, C and D of
Figure 1.
For future research, we will consider multiple data
sources to increase the robustness of the designed maps.
As explained in Figure 1, we can use RAPID siRNA
screens to validate single points of failures predicted by
our TIM approach. Furthermore, RNAseq and protein
phosphoarray data can be used to further revise the cir-
cuit. Finally, time series data can be used to incorporate
dynamics in the modeling framework. For combination
therapy design, we can use the TIM framework to formu-
late control strategies with various constraints. Some pos-
sibilities are (a) minimal toxicity, (b) anticipating evolving
drug resistance, and (c) success over a family of TIMs
representing variations of a tumor. For case (a), we can
assume that the toxicity of a drug or drug combination
is proportional to the number of targets being inhibited
by the drug(s) and search for the drug combination with
high sensitivity but low set of target inhibitions. For case
(b), we would want to avoid resistance and thus would
like to inhibit more than one independent blocking path-
way such that for the scenario when resistance to one of
the blocking pathways develops, the other independent
pathway(s) can still keep the tumor under check. In other
words, we would be interested in selecting a set of tar-
gets that can be divided into two or more non-intersecting
sets such that the sensitivity of each set is higher than
a threshold. For case (c), the goal is to design control
policies for the scenario when the exact pathway is not
known but it belongs to a collection of pathways. The
uncertainty can arise when the experimental data is not
sufficient enough to produce a unique pathwaymap or the
current pathway may evolve into one of the different path-
ways obtained from tissues with same type of cancer. This
can approached from a worst case perspective [37] or a
Bayesian perspective [38].
In conclusion, the proposed framework provides a
unique input-output based methodology to model a can-
cer pathway and predict the effectiveness of targeted
drugs. This framework can be developed as a viable
approach for personalized cancer therapy. To aide in the
usage of our framework, we have developed a Graphical
User Interface which implements in an easy to use way
the algorithms and equations presented in this paper. It is
built in MATLAB, but is distributed as a compiled exe-
cutable; as such, it is usable in a Windows environment
by downloading the MATLAB Compile Runtime (MCR)
Environment, which is free to download and requires
no MATLAB installation. It is available online at: http://
cvial.ece.ttu.edu/ranadippal/research.html under the Tar-
get Inhibition Map approach to inference of cancer path-
ways heading.
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